

AMDOCS LTD
Form SC TO-I
February 13, 2009

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE TO
(RULE 14d-100)
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934**

AMDOCS LIMITED
(Name of Subject Company (Issuer))
Amdocs Limited
(Name of Filing Persons (Offeror))

0.50% Convertible Senior Notes due 2024
(Title of Class of Securities)
02342TAC3
02342TAD1
(CUSIP Number of Class of Securities)

Amdocs, Inc.
1390 Timberlake Manor Parkway, Chesterfield, Missouri 63017
Attention: Thomas G. O'Brien, Treasurer
(314) 212-8328
(Name, address and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

The Commission is requested to send copies of all communications to:
Robert A. Schwed, Esq.
WilmerHale LLP
300 Park Avenue
New York, New York 10022
(212) 937-7200

CALCULATION OF FILING FEE

Transaction Valuation(1)	Amount of Filing Fee(2)
\$331,869,114	\$13,043

(1) Determined pursuant to Rule 0-11(b)(1) of the Securities Exchange Act of 1934. Based upon the maximum

amount of cash
that might be
paid for the
0.50%
Convertible
Senior Notes
due 2024.

- (2) The amount of
the filing fee,
calculated in
accordance with
Section 13(e)(3)
of the Securities
Exchange Act of
1934, as
amended, equals
\$39.30 per
\$1,000,000 of
the value of
securities
proposed to be
purchased.

- Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: Not applicable.

Filing party: Not applicable.

Form or Registration No.: Not applicable.

Date filed: Not applicable.

- Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- third party tender offer subject to Rule 14d-1.

- issuer tender offer subject to Rule 13e-4.

- going-private transaction subject to Rule 13e-3.

- amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

- Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

- Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

TABLE OF CONTENTS

TENDER OFFER

Item 1. Summary Term Sheet.

Item 2. Subject Company Information.

Item 3. Identity and Background of Filing Person.

Item 4. Terms of the Transaction.

Item 5. Past Contacts, Transactions, Negotiations and Agreements.

Item 6. Purposes of the Transaction and Plans or Proposals.

Item 7. Source and Amount of Funds or Other Consideration.

Item 8. Interest in Securities of the Subject Company.

Item 9. Persons/Assets, Retained, Employed, Compensated or Used.

Item 10. Financial Statements.

Item 11. Additional Information.

Item 12. Exhibits.

Item 13. Information Required by Schedule 13E-3.

SIGNATURE

EXHIBIT INDEX

EX-99.A.1.I: NOTICE OF PUT RIGHT AND OFFER TO PURCHASE

EX-99.A.1.II: LETTER OF TRANSMITTAL

EX-99.A.1.III: LETTER TO CLIENTS

EX-99.A.1.IV: BROKER DEALER LETTER

EX-99.A.1.V: W-9 GUIDELINES

EX-99.A.5.I: PRESS RELEASE

Table of Contents**TENDER OFFER**

This Tender Offer Statement on Schedule TO relates to an offer (the Offer) by Amdocs Limited, a company organized under the laws of the Island of Guernsey (Amdocs), to purchase for cash, on the terms and subject to the conditions set forth in the attached Notice of Put Right and Offer to Purchase, dated February 13, 2009 (the Offer to Purchase), and Letter of Transmittal (the Letter of Transmittal), any and all of its outstanding 0.50% Convertible Senior Notes due 2024. Copies of the Offer to Purchase and the Letter of Transmittal are filed as exhibits (a)(1)(i) and (a)(1)(ii), respectively, hereto. Pursuant to General Instruction F to Schedule TO, information contained in the Offer to Purchase is hereby incorporated by reference in the answers to items in this Statement.

Item 1. Summary Term Sheet.

The information set forth in the section of the Offer to Purchase captioned Summary Term Sheet is incorporated herein by reference.

Item 2. Subject Company Information.

(a) The name of the issuer is Amdocs Limited, a company organized under the laws of the Island of Guernsey. Our registered office is located in Suite 5, Tower Hill House Le Bordage, St. Peter Port, Guernsey, GY1 3QT, and the telephone number at that location is 011-44-1481-728444. The executive offices of our principal subsidiary in the United States are located at 1390 Timberlake Manor Parkway, Chesterfield, Missouri 63017, and the telephone number at that location is (314) 212-8328. The information set forth in the Offer to Purchase in the section captioned Information About Amdocs is incorporated herein by reference.

(b) The securities that are subject to this offer are the 0.50% Convertible Senior Notes due 2024 of Amdocs Limited, or the notes. As of the date of this statement, there was \$331,800,000 aggregate principal amount of the notes outstanding.

(c) The information set forth in the Offer to Purchase in the section captioned The Offer Information about the Notes Trading Market is incorporated herein by reference.

On February 11, 2009, the last reported sale price for Amdocs ordinary shares was \$18.59 per share.

Item 3. Identity and Background of Filing Person.

(a) The information set forth under Item 1 and Item 2(a) above is incorporated herein by reference. Amdocs is both the filing person and the subject company.

As required by General Instruction C to Schedule TO promulgated by the U.S. Securities and Exchange Commission, the following persons are directors and/or executive officers and/or controlling persons of Amdocs:

Bruce K. Anderson	Director, Amdocs Limited
Adrian Gardner	Director, Amdocs Limited
Charles E. Foster	Director, Amdocs Limited
James S. Kahan	Director, Amdocs Limited
Zohar Zisapel	Director, Amdocs Limited
Julian A. Brodsky	Director, Amdocs Limited
Eli Gelman	Director, Amdocs Limited
Nehemia Lemelbaum	Director, Amdocs Limited
John T. McLennan	Director, Amdocs Limited
Robert A. Minicucci	Director, Amdocs Limited
Simon Olswang	Director, Amdocs Limited
Dov Baharav	Director, Amdocs Limited; President and Chief Executive Officer, Amdocs Management Limited
Tamar Rapaport Dagim	Senior Vice President and Chief Financial Officer, Amdocs Management Limited
James Liang	Senior Vice President and Chief Strategy Officer, Amdocs, Inc.
Ayal Shiran	Senior Vice President and Head of Customer Business Group

Table of Contents

Item 7. *Source and Amount of Funds or Other Consideration.*

(a) The information set forth in the Offer to Purchase in the section captioned "The Offer - Source and Amount of Funds" is incorporated herein by reference.

(b) Not applicable.

(d) The information set forth in the Offer to Purchase in the section captioned "The Offer - Source and Amount of Funds" is incorporated herein by reference.

Item 8. *Interest in Securities of the Subject Company.*

(a) To the best knowledge of Amdocs, no notes are beneficially owned by any person whose ownership would be required to be disclosed by this item.

(b) None.

Item 9. *Persons/Assets, Retained, Employed, Compensated or Used.*

(a) The information set forth in the Offer to Purchase in the section captioned "Paying Agent; Fees and Expenses" is incorporated herein by reference.

Item 10. *Financial Statements.*

(a) Amdocs does not believe it is required to include such information due to the fact that such information is not material because, among other reasons, the consideration offered consists solely of cash, the offer is not subject to any financing condition, the offeror is a public reporting company that files reports electronically under EDGAR and the Offer is for all outstanding notes.

(b) Not applicable.

Item 11. *Additional Information.*

Agreements, Regulatory Requirements and Legal Proceedings.

(a)(1) None.

(a)(2) None.

(a)(3) None.

(a)(4) None.

(a)(5) None.

Other Material Information.

(b) The information set forth in the Offer to Purchase and the Letter of Transmittal dated as of February 13, 2009, copies of which are attached hereto as Exhibits (a)(1)(i) and (a)(1)(ii), respectively, is incorporated herein by reference.

Table of Contents

Item 12. Exhibits.

- (a)(1)(i) Notice of Put Right and Offer to Purchase, dated February 13, 2009.*
- (a)(1)(ii) Letter of Transmittal, dated February 13, 2009.*
- (a)(1)(iii) Letter to Clients, dated February 13, 2009.*
- (a)(1)(iv) Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees, dated February 13, 2009.*
- (a)(1)(v) Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.*
- (a)(5)(i) Press Release Regarding Offer, dated February 13, 2009.*
- (b) Credit Agreement, dated as of November 27, 2007, among Amdocs Limited, certain of its subsidiaries, the lenders from time to time party thereto, JPMorgan Chase Bank, N.A., as administrative agent, J.P. Morgan Europe Limited, as London agent, and JPMorgan Chase Bank, N.A., Toronto branch, as Canadian agent (incorporated by reference to Exhibit 4.b.9 to Amdocs Annual Report on Form 20-F, filed December 3, 2007).
- (d)(1) Indenture, dated as of March 5, 2004, between Amdocs Limited and The Bank of New York Mellon (formerly known as The Bank of New York), as trustee, for 0.50% Convertible Senior Notes due 2024 (incorporated by reference to Exhibit 99.1 to Amdocs Report on Form 6-K, filed March 5, 2004).
- (d)(2) Registration Rights Agreement, dated as of March 5, 2004, between Amdocs Limited and Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated (incorporated by reference to Exhibit 99.2 to Amdocs Report on Form 6-K, filed March 5, 2004).
- (g) None.
- (h) None.

* Filed herewith

Item 13. Information Required by Schedule 13E-3.

Not applicable.

Table of Contents

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Amdocs Limited

By: /s/ Thomas G. O Brien

Thomas G. O Brien
Treasurer and Secretary
Authorized U.S. Representative

Date: February 13, 2009

6

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description
(a)(1)(i)	Notice of Put Right and Offer to Purchase, dated February 13, 2009.*
(a)(1)(ii)	Letter of Transmittal, dated February 13, 2009.*
(a)(1)(iii)	Letter to Clients, dated February 13, 2009.*
(a)(1)(iv)	Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees, dated February 13, 2009.*
(a)(1)(v)	Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.*
(a)(5)(i)	Press Release Regarding Offer, dated February 13, 2009.*
(b)	Credit Agreement, dated as of November 27, 2007, among Amdocs Limited, certain of its subsidiaries, the lenders from time to time party thereto, JPMorgan Chase Bank, N.A., as administrative agent, J.P. Morgan Europe Limited, as London agent, and JPMorgan Chase Bank, N.A., Toronto branch, as Canadian agent (incorporated by reference to Exhibit 4.b.9 to Amdocs Annual Report on Form 20-F, filed December 3, 2007).
(d)(1)	Indenture, dated as of March 5, 2004, between Amdocs Limited and The Bank of New York Mellon (formerly known as The Bank of New York), as trustee, for 0.50% Convertible Senior Notes due 2024 (incorporated by reference to Exhibit 99.1 to Amdocs Report on Form 6-K, filed March 5, 2004).
(d)(2)	Registration Rights Agreement, dated as of March 5, 2004, between Amdocs Limited and Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated (incorporated by reference to Exhibit 99.2 to Amdocs Report on Form 6-K, filed March 5, 2004).
(g)	None.
(h)	None.

* Filed herewith